Recommendations on eligibility to PRIME scheme Adopted at the CHMP meeting of 18-21 April 2017
During its April 2017 meeting, the CHMP reviewed 5 recommendations for eligibility to PRIME: 1 was granted and 4 were denied. The individual outcomes adopted this month are listed below.
serotype 5 containing human factor IX gene (AMT-060) * Name of the active substance, INN, common name, chemical name or company code. SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency’s SME office. Other types of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.
Recommendations on eligibility to PRIME scheme EMA/668824/2016
Page 2/4
Eligibility denied Substance type
Therapeutic area
Therapeutic indication
Type of data supporting
Type of
request
applicant
Other
Chemical
Oncology
Treatment of patients with advanced or metastatic ALKpositive non-small cell lung cancer
Nonclinical
Advanced therapy
Oncology
Treatment of metastatic melanoma
Nonclinical
+ Clinical exploratory SME
+ Clinical exploratory Advanced therapy
Cardiovascular Diseases
Treatment of chronic cardiac ischemia
Nonclinical
Academic
+ Clinical exploratory Chemical
Neurology
Treatment of Rett syndrome
Nonclinical
SME
+ Tolerability first in man SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency’s SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.
Recommendations on eligibility to PRIME scheme EMA/668824/2016
Page 3/4
Cumulative overview of recommendations on PRIME eligibility requests adopted by 23 March 2017 By therapeutic area
By type of applicant
* One eligible product has subsequently been withdrawn from the scheme at the applicant’s request
Out of scope indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area. Recommendations on eligibility to PRIME scheme EMA/668824/2016
Recommendations on eligibility to PRIME scheme - European ...
Apr 26, 2017 - supporting request. Type of applicant ... Name of the active substance, INN, common name, chemical name or company code. SME applicants ...
Mar 29, 2017 - SME. Chemical. Oncology. Treatment of locally advanced or ... the scope of the scheme or with a format and content inadequate to support.
Jul 26, 2017 - 30 Churchill Place â Canary Wharf â London E14 5EU â United ... Name of the active substance, INN, common name, chemical name or company code. ... of the scheme or with a format and content inadequate to support.
3 days ago - Name*. Substance type. Therapeutic area. Therapeutic indication. Type of data supporting request. Type of applicant. Adeno-associated viral.
Nov 16, 2016 - SME applicants are micro-, small-and medium-sized-enterprises ... of the scheme or with a format and content inadequate to support their.
Nov 15, 2017 - Substance type Therapeutic area. Therapeutic indication. Type of data supporting request. Type of applicant. Autologous T lymphocyte- enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor
Oct 18, 2017 - Additionally, the CHMP reviewed data on progress to proof of concept and confirmed eligibility for A4250 in the treatment of progressive familial intrahepatic cholestasis, which was initially granted eligibility to the scheme at early
Jul 4, 2018 - *This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and ...
Mar 1, 2017 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom ... active substance, INN, common name, chemical name or company code. ... of the scheme or with a format and content inadequate to support their.
Dec 20, 2017 - Press office. Recommendations on eligibility to PRIME scheme. Adopted at the CHMP meeting of 11-14 December 2017. During its December 2017 ... requests received but not started by EMA as they were deemed outside the scope of the scheme
Jun 29, 2016 - Name of the active substance, INN, common name, chemical name or company code. SME applicants are micro-, small-and medium-sized-enterprises ... of the scheme or with a format and content inadequate to support their.
Whoops! There was a problem previewing this document. Retrying... Download. Connect more apps... Try one of the apps below to open or edit this item. ELIGIBILITY CONDTIONS AND SCHEME OF TEST FOR M.C.A..pdf. ELIGIBILITY CONDTIONS AND SCHEME OF TEST FO
>PRIME aims to bring promising medicines that meet regulatory requirements to patients earlier by optimising and supporting their development. >The scheme ...
CITIZEN'S RECOMMENDATIONS BASED ON THE SPOT OF VIOLENCE IN MATIRANGA.pdf. CITIZEN'S RECOMMENDATIONS BASED ON THE SPOT OF VIOLENCE IN MATIRANGA.pdf. Open. Extract. Open with. Sign In. Main menu. Displaying CITIZEN'S RECOMMENDATIONS BASED ON THE SPOT O
